Adicet Bio IncNASDAQ ACET Stock Report

Adicet Bio, Inc. is a biotechnology company, which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company is headquartered in Boston, Massachusetts and currently employs 132 full-time employees. The company went IPO on 2018-01-26. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CAR) and T cell receptor-like antibodies (TCRL), to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response and improve persistence for durable activity in patients. Its lead product candidate, ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is under Phase I study for the treatment of Non-Hodgkin's Lymphoma. Its pipeline also includes ADI-002, an allogeneic gamma delta CAR-T cell therapy expressing a GPC3-targeted CAR and a cell intrinsic soluble form of interluiken-15, for the treatment of solid tumors. In addition, it is engaged in discovery and preclinical stage activities of its pipeline of product candidates for both hematological malignancies and solid tumors.